Mixed germ cell tumor

Mixed germ cell tumor (also known as mixed malignant germ cell tumor) is a rare neoplasm composed of two or more types of germ cell tumor components. These tumors most commonly arise in the gonads (ovaries and testes) but can also occur in extragonadal midline locations such as the mediastinum, retroperitoneum, and central nervous system (particularly the pineal and suprasellar regions). The different histological components may include combinations of seminoma/dysgerminoma/germinoma, embryonal carcinoma, yolk sac tumor (endodermal sinus tumor), choriocarcinoma, and teratoma (mature or immature). The clinical behavior and prognosis of mixed germ cell tumors depend on the specific components present and their relative proportions, with choriocarcinoma and embryonal carcinoma elements generally conferring a more aggressive course. Patients may present with a palpable mass, pain, or swelling in the affected area. Testicular mixed germ cell tumors typically present as a painless testicular mass in young men, while ovarian mixed germ cell tumors may cause abdominal pain, distension, or a pelvic mass in young women. Tumors that produce human chorionic gonadotropin (hCG) or alpha-fetoprotein (AFP) may cause elevated serum tumor markers, which are important for diagnosis and monitoring treatment response. Intracranial tumors may present with headaches, visual disturbances, diabetes insipidus, or signs of increased intracranial pressure. Treatment typically involves a multimodal approach including surgical resection and platinum-based combination chemotherapy, most commonly the BEP regimen (bleomycin, etoposide, and cisplatin). Radiation therapy may be used in certain cases, particularly for intracranial germ cell tumors. The overall prognosis for mixed germ cell tumors has improved significantly with modern chemotherapy regimens, though outcomes vary depending on tumor location, stage at diagnosis, histological composition, and response to initial treatment. Regular monitoring of serum tumor markers (AFP, hCG, and lactate dehydrogenase) is essential during and after treatment to assess response and detect recurrence.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Mixed germ cell tumor